Semnur Pharmaceuticals, Inc. has entered into a binding term sheet with iHolding Group LLP for a proposed $100 million investment. iHolding Group LLP plans to purchase $100 million worth of newly issued Semnur common stock at an expected price of $10.00 per share, representing approximately 10 million shares. The investment proceeds are intended to support the advancement of Semnur's pipeline, particularly the Phase 3 clinical program for SEMDEXA (SP-102), along with product development, commercialization, acquisitions, working capital, and general corporate purposes. The transaction is contingent upon customary due diligence, negotiation and execution of definitive agreements, board approvals, and regulatory approvals. There is no guarantee that the definitive agreements will be executed or that the investment will be consummated as described.